# M701

Source: https://onco.cc/drugs/m701/  
OnCo record `m701` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

M701 is Wuhan YZY Biopharma's EpCAM-CD3 bispecific antibody infused into the abdomen to control malignant ascites, in a phase 3 trial in China.

## Summary

Malignant ascites, fluid that builds up in the abdomen from cancer spread to the peritoneum, is drained repeatedly for symptom relief. Catumaxomab, an EpCAM-CD3 bispecific, was approved in Europe in 2009 for this use and later withdrawn. M701 revives the approach: YZY Biopharma's phase 3 trial in China compares intraperitoneal M701 with paracentesis alone for the time until fluid must be drained again.

## Fields

- Kind: Treatment
- Status: phase-3
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Modality: Bispecific antibody (EpCAM x CD3), intraperitoneal
- Mechanism: One arm binds EpCAM on tumour cells in the ascites fluid and the other engages CD3 on T cells, bringing T cells to kill the cancer cells that cause malignant ascites, the mechanism of the earlier drug catumaxomab.

## Sources

- ClinicalTrials.gov: trials of M701: https://clinicaltrials.gov/search?intr=M701

## Connected records

- cancers: [Gastric & gastro-oesophageal junction cancer](https://onco.cc/cancers/gastric/), [Ovarian cancer](https://onco.cc/cancers/ovarian/)
- technologies: [Bispecific antibodies](https://onco.cc/technologies/bispecific-antibody/), [T-cell engagers (bispecific)](https://onco.cc/technologies/t-cell-engager/)
- targets: [CD3](https://onco.cc/targets/cd3/), [EpCAM](https://onco.cc/targets/epcam/)
- trials: [Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody](https://onco.cc/trials/nct06432296/)

---
JSON: https://onco.cc/api/v1/entities/m701.json